Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial

相似書籍

• Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial
  由: Wolinsky, Jerry S., et al.
  出版: (2018)
• An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability
  由: Wolinsky, Jerry S, et al.
  出版: (2020)
• Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
  由: Turner, Benjamin, et al.
  出版: (2019)
• Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO
  由: Gibiansky, Ekaterina, et al.
  出版: (2020)
• Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension
  由: Hauser, Stephen L., et al.
  出版: (2020)